1. IAEA-TECDOC-1549. Criteria for palliation of bone metastases—clinical applications. Austria, Vienna: IAEA; 2007.
2. Lipton A. Pathophysiology of Bone Metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol. 2004;2:205–20.
3. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34:1031–6.
4. Rajendran JG, Eary JF, Bensinger W, Durack LD, Vernon C, Fritzberg A. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med. 2002;43:1383–90.
5. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451–8.